Ceapro Inc (CRPOF) 1.4597 $CRPOF Ceapro Inc. Closes an

New Post Public Reply Private Reply Replies (0) Message Board

Jul 28, 2016 at 9:14 PM

Ceapro Inc (CRPOF) 1.4597 $CRPOF

Ceapro Inc. Closes an Initial Tranche of a Brokered Private Placement
Marketwired - Mon Jul 11, 7:01AM CDT
EDMONTON, ALBERTA--(Marketwired - Jul 11, 2016) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"

, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed the first tranche of its previously announced brokered private placement (the "Offering"

and increased the maximum size of the Offering from $5,750,000 to $10,000,000. The first tranche resulted in the issuance of 5,348,592 units (each, a "Unit"

, including 405,500 Units held in escrow pending final approval of the Offering by the TSX Venture Exchange, each issued at a price of $1.06 per Unit, which resulted in gross proceeds of $5,669,508. Each Unit consisted of one common share (each a "Purchased Share"

and one-half common share purchase warrant (each a "Warrant"

. Each Warrant entitles the holder thereof to acquire one additional common share (each a "Warrant Share"

at an exercise price of $1.50 for a period of 24 months following the closing of the Offering. The second tranche of the Offering is expected to close on or about July 13, 2016.
CZO.VN: 1.980 (-0.010)

Ceapro Inc. Announces No Material Change
Marketwired - Thu Jul 07, 8:25AM CDT
EDMONTON, ALBERTA--(Marketwired - Jul 7, 2016) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"

, a growth-stage biotechnology company focused on the development and active ingredients for healthcare and cosmetic industries, is issuing this press release in response to a recent request by the Investment Industry Regulatory Organization of Canada ("IIROC"

to comment on recent trading activity in its stock.
CZO.VN: 1.980 (-0.010)

Ceapro Inc. Announces Brokered Private Placement
Marketwire Canada - Thu Jun 09, 6:06AM CDT
EDMONTON, ALBERTA--(Marketwired - Jun 9, 2016) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"

as sole agent to undertake a brokered private placement financing, on a commercially reasonable basis, of 4,716,981 units (each, a "Unit"

at a price of $1.06 per Unit for gross proceeds to the Company of $5,000,000 (the "Offering"

.
CZO.VN: 1.980 (-0.010)

Ceapro Announces Election of Directors at 2016 Shareholders' Meeting
Marketwired - Thu Jun 02, 3:06PM CDT
EDMONTON, ALBERTA--(Marketwired - Jun 2, 2016) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"

, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors, Mr. Gilles Gagnon, Dr. Ulrich Kosciessa, Dr. William W. Li, Mr. Don Oborowsky, Mr. Glenn R. Rourke and Mr. John Zupancic, were elected to serve for a one-year term at its annual meeting of shareholders held on June 1, 2016.
CZO.VN: 1.980 (-0.010)

Ceapro Inc. Reports 2016 First Quarter Financial Results and Provides Corporate Update
Marketwired - Wed May 18, 7:03AM CDT
Ceapro Posts Highest Quarterly Revenues Reported in Company's History
CZO.VN: 1.980 (-0.010)

Ceapro Inc. Presents Its PGX Technology at the 15th European Meeting on Supercritical Fluids
Marketwired - Mon May 09, 7:03AM CDT
EDMONTON, ALBERTA--(Marketwired - May 9, 2016) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"

, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that it presented this morning its PGX Technology at the 15th European Meeting on Supercritical Fluids being held in Essen, Germany.
CZO.VN: 1.980 (-0.010)

Ceapro Inc. Provides 2015 Business Highlights and 2016 Business Outlook
Marketwired - Mon Apr 18, 6:35AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"

, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today provided a business update for the year ended December 31, 2015 and a 2016 business outlook.
CZO.VN: 1.980 (-0.010)

Ceapro Inc. Reports 2015 Financial Results, Best Financial Year in Company's History
Marketwired - Thu Apr 14, 6:36AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"

, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the twelve-months ended December 31, 2015. The Company's 2015 Financial Results reveal the best year in Ceapro's history.
CZO.VN: 1.980 (-0.010)

Ceapro Announces Renewal of a Long Term License and Distribution Agreement With Symrise
Marketwired - Wed Apr 06, 6:05AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or "the Company"

a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the signing of a new long term agreement with German-based multinational, Symrise AG, for the distribution and commercialization of Ceapro's high value active ingredients to major key international players in the cosmetic market.
CZO.VN: 1.980 (-0.010)

Ceapro Inc. Issued U.S. Patent for Enabling Pressurized Gas Expanded (PGX) Technology
Marketwired - Wed Feb 03, 7:03AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"

, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that the Company has received issuance from the U.S. Patent and Trademark Office ("USPTO"

for U.S. Patent No. 13/638,254 titled, "Supercritical Fluid Treatment of High Molecular Weight Biopolymers."
CZO.VN: 1.980 (-0.010)

Ceapro to Present at Noble Financial Capital Markets' 12th Annual Investor Conference
Marketwired - Wed Jan 13, 7:03AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"

, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at NobleCon12, the Noble Financial Capital Markets' 12th Annual Investor Conference, on Tuesday, January 19, 2016 at 2:30 p.m. ET in Sandpiper Bay, FL.
CZO.VN: 1.980 (-0.010)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Simple Home Upgrades That Boost Value Fast

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

xFusion Tackles Cooling and Power at OCP 2026

Bracing for an AI Revolution Ah, the world of AI — it's like the wild west out there, with data centers struggling to keep up as workloads skyrocket. Enter xFusion, a veteran in the computing infrastructure game, rolling out some seriously impressive tech at the 2026 Open Compute Project (OCP) Global Summit. The company's latest offering showcases how they're tackling...

Canada and Ukraine Fortify Defense with UGV Partnership

New Defense Fronts: Canada and Ukraine Join Forces October 13, 2026, marks an important day in Ottawa's defense narrative with Dominion Dynamics and Ukraine's TENCORE kicking off a robust partnership. They're not just collaborating; they're plugging into each other's strengths to build TerMIT uncrewed ground vehicles (UGVs) on Canadian soil. These aren't gizmos you find...

Paradigm Therapeutics: A Beacon in Rare Diseases

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

Puori Protein Transparency Pays Off Amid Lead Scare

Puori's Moment of Reckoning The world of nutritional supplements is no stranger to controversy, but when Puori found itself caught in the storm of the Consumer Reports investigation last year, it chose a road less traveled: transparency and accountability. Faced with alarming news that over two-thirds of tested protein powders exceeded California's Proposition 65 lead...

Marshall Goldman Expands Footprint with Marino Acquisition

Revving Up in Florida: Marshall Goldman's Strategic Leap If you're tuned into the luxury car scene, you probably already heard Marshall Goldman is making moves into Florida. Buying Marino Performance Motors of West Palm Beach isn't just another notch on their belt—it's a strategic leap into their second-largest market. This ain't merely about showroom floor space. Think...

Franco-Nevada's Q3 Results Loom: Investors Ready

Gearing Up: Franco-Nevada's Q3 Numbers on the Horizon You know the drill! Franco-Nevada's third quarter results won't just trickle in—they'll set the tone for the months ahead. Mark your calendar: November 11th after the market closes is the magic hour when you'll get the skinny on their Q3 performance. The next morning, bright and early at 8:00 AM ET, they'll hash it...

Montesodi 2023: A Fresh Chapter in Chianti Excellence

A Glass Filled with History and Nature's Whimsy When you pour a glass of Montesodi 2023, you’re not just tasting wine but a story—a saga that blends Tuscany’s rich vineyard history with last year's unpredictable weather. Marchesi Frescobaldi, a name that’s seen it all over its thousand years, has once again shown us how resilience and tradition can marry with...

Home Buying: Unmasking All the Real Budget Costs

Home Buying: More Costs Than Meets the Eye Let's face it, buying a home is no stroll in the park. It's a tangled web of numbers and surprises that can leave even the savviest buyer in a daze. Thank goodness for articles like the one from HelloNation featuring Serena LoPiccolo-Smith, which make the invisible visible when it comes to the financial intricacies of home...

Cogent Communications' Q3 2026 Earnings Call Details

Cue the Countdown: Cogent’s Earnings Call Looms Another quarter rolls by, and with it comes Cogent Communications' chance to strut—or stumble—before the crowd. Their third-quarter earnings call on November 5, 2026, is like the opening bell for a stock that's zipped through more ups and downs than a tired bullfighter's routine. What the call reveals on that crisp...